Table 5 Association of COL11A1 variant E with clinicopathological characteristics in breast cancer tissues
Presence or absence of variant E (qualitative) | Number of E copies (percentile: 50 th ) (quantitative) | Copies of variant E (for positive samples) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Clinical features | N (%) | Absence | Presence | Pearson χ 2 or Fisher’s exact | Ν (%) | Low | High | Pearson χ 2 or Fisher’s exact | Median | Mann–Whitney |
n (%) | n (%) | p-value | n (%) | n (%) | p-value | p-value | ||||
Age Group | 0.450 | 0.478 | 0.639 | |||||||
< =50 years | 26 (35.6) | 10 (41.7) | 16 (32.7) | 16 (32.7) | 9 (37.5) | 7 (28.0) | 579,678 | |||
> 50 years | 47 (64.4) | 14 (58.3) | 33 (67.3) | 33 (67.3) | 15 (62.5) | 18 (72.0) | 351,707 | |||
Tumor Size | 0.912 | 0.273 | 0.875 | |||||||
≤ 2.0 cm | 59 (67.0) | 19 (67.9) | 40 (66.7) | 40 (66.7) | 22 (73.3) | 18 (60.0) | 493,555 | |||
> 2.0 cm | 29 (33.0) | 9 (32.1) | 20 (33.3) | 20 (33.3) | 8 (26.7) | 12 (40.0) | 106,231 | |||
Histopathological Type | 0.820 | 0.520 | 0.498 | |||||||
Lobular & rest | 18 (20.0) | 6 (21.4) | 12 (19.4) | 12 (19.4) | 7 (22.6) | 5 (16.1) | 372,702 | |||
Intraductal infiltrating | 72 (80.0) | 22 (78.6) | 50 (80.6) | 50 (80.6) | 24 (77.4) | 26 (83.9) | 352,048 | |||
Lymph-node Involvement | 0.037 | 0.435 | 0.130 | |||||||
Negative (Ν0) | 55 (67.1) | 23 (82.1) | 32 (59.3) | 32 (59.3) | 14 (53.8) | 18 (64.3) | 550,330 | |||
Positive (Ν+) | 27 (32.9) | 5 (17.9) | 22 (40.7) | 22 (40.7) | 12 (46.2) | 10 (35.7) | 145,674 | |||
Metastasis | 0.041 | 1.000 | 0.307 | |||||||
Negative M0 | 47 (85.5) | 20 (100.0) | 27 (77.1) | 27 (77.1) | 15 (78.9) | 12 (75.0) | 259,540 | |||
Positive M1 | 8 (14.5) | 0 (0.0) | 8 (22.9) | 8 (22.9) | 4 (21.1) | 4 (25.0) | 467,861 | |||
Grade | 0.601 | 0.237 | 0.650 | |||||||
Low (1–2) | 60 (73.2) | 20 (76.9) | 40 (71.4) | 40 (71.4) | 18 (64.3) | 22 (78.6) | 401,804 | |||
High (3) | 22 (26.8) | 6 (23.1) | 16 (28.6) | 16 (28.6) | 10 (35.7) | 6 (21.4) | 119,249 | |||
Estrogen-receptor Status | 0.367 | 0.876 | 0.867 | |||||||
Negative | 21 (23.9) | 5 (17.9) | 16 (26.7) | 16 (26.7) | 8 (25.8) | 8 (27.6) | 228,414 | |||
Positive | 67 (76.1) | 23 (82.1) | 44 (73.3) | 44 (73.3) | 23 (74.2) | 21 (72.4) | 411,925 | |||
Progesterone-receptor Status | 0.453 | 0.287 | 0.174 | |||||||
Negative | 46 (52.3) | 13 (46.4) | 33 (55.0) | 33 (55.0) | 15 (48.4) | 18 (62.1) | 305,909 | |||
Positive | 42 (47.7) | 15 (53.6) | 27 (45.0) | 27 (45.0) | 16 (51.6) | 11 (37.9) | 432,753 | |||
HER2 Overexpression Status | 0.517 | 1.000 | 0.592 | |||||||
Negative | 72 (81.8) | 24 (85.7) | 48 (80.0) | 48 (80.0) | 24 (80.0) | 24 (80.0) | 430,475 | |||
Positive | 16 (18.2) | 4 (14.3) | 12 (20.0) | 12 (20.0) | 6 (20.0) | 6 (20.0) | 104,271 | |||
TNBC, n (%) | 0.732 | 0.100 | 0.146 | |||||||
Yes | 17 (19.3) | 6 (21.4) | 11 (18.3) | 11 (18.3) | 3 (9.7) | 8 (27.6) | 323,558 | |||
No | 71 (80.7) | 22 (78.6) | 49 (81.7) | 49 (81.7) | 28 (90.3) | 21 (72.4) | 371,840 | |||